When $99 means $178: the semaglutide membership trap
A growing share of telehealth programmes advertise a medication price and bill a mandatory platform fee separately. The advertised figure is real; it is simply not the figure that reaches your statement.
| Structure | Advertised medication | Mandatory fee | Real monthly | Understated by |
|---|---|---|---|---|
| Membership model A | $99 | $79 | $178 | 80% |
| Membership model B | $149 | $75 | $224 | 50% |
| Membership model C | $196 | $99 | $295 | 51% |
| Plan fee model | $149 | $25 | $174 | 17% |
| Flat all-in | $119 | none | $119 | 0% |
What a membership adds over twelve months
Why the structure exists
Two defensible reasons and one commercial one. Splitting the fee lets a programme bill medication through insurance where it applies while charging separately for clinical services, and it lets a programme keep serving a patient whose medication comes from elsewhere.
The commercial reason is that a lower advertised number wins comparison tables. Most published round-ups compare medication prices rather than totals, so a programme with an aggressive fee structure appears near the top of lists it would not otherwise reach.
When a membership earns its cost
When you use it. Unlimited clinician messaging is genuinely valuable during titration, when dose questions arrive weekly. At stable maintenance it is close to idle.
Ask what happens to your prescription if the membership lapses mid-supply. A programme that stops medication when a fee lapses has let a business model reach into a clinical relationship.
How to spot it in ninety seconds
Search the pricing page for membership, programme fee, platform fee and subscription. Then ask one question in writing: what will I pay in total in month six at a 2.4 mg maintenance dose, including every recurring charge. A flat all-in programme answers in one sentence.